(CMPS) Compass Pathways - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 714m USD | Total Return: 83.1% in 12m

Psilocybin Therapy, Depression Treatment
Total Rating 40
Safety 54
Buy Signal -1.08
Medical Care Facilities
Industry Rotation: -12.9
Market Cap: 714M
Avg Turnover: 10.6M USD
ATR: 6.95%
Peers RS (IBD): 81.7
Risk 5d forecast
Volatility80.0%
Rel. Tail Risk-12.4%
Reward TTM
Sharpe Ratio1.19
Alpha60.68
Character TTM
Beta1.257
Beta Downside2.678
Drawdowns 3y
Max DD81.00%
CAGR/Max DD-0.22
EPS (Earnings per Share) EPS (Earnings per Share) of CMPS over the last years for every Quarter: "2021-03": -0.35, "2021-06": -0.44, "2021-09": -0.38, "2021-12": -0.61, "2022-03": -0.5, "2022-06": -0.5, "2022-09": -0.43, "2022-12": -0.73, "2023-03": -0.57, "2023-06": -0.62, "2023-09": -0.67, "2023-12": -0.53, "2024-03": -0.55, "2024-06": -0.56, "2024-09": -0.56, "2024-12": -0.63, "2025-03": -0.4185, "2025-06": -0.4114, "2025-09": -1.44, "2025-12": -0.6065, "2026-03": 0,
EPS CAGR: 11.46%
EPS Trend: 7.7%
Last SUE: 1.23
Qual. Beats: 1
Revenue Revenue of CMPS over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 3.682752, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: null,
Rev. CAGR: 0.00%
Rev. Trend: -2.8%
Last SUE: 0.00
Qual. Beats: 0

Warnings

Share dilution 36.8% YoY - potential capital distress

Interest Coverage Ratio -52.4 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: CMPS Compass Pathways

Compass Pathways plc (NASDAQ: CMPS) is a UK-based biotechnology firm developing psilocybin-based therapies for mental-health disorders, notably its COMP360 program currently in Phase III for treatment-resistant depression and Phase II for PTSD and anorexia nervosa.

As of the latest filing (Q4 2024), the company reported a cash runway of approximately $55 million, a net loss of $12.3 million for the quarter, and a market capitalization near $220 million, reflecting investor focus on its upcoming Phase III readout expected in H2 2025.

The mental-health sector is experiencing robust growth, with the global treatment-resistant depression market projected to expand at a CAGR of ~7% through 2030, while regulatory pathways for psychedelic therapies are gaining traction in the U.S. and EU, potentially accelerating market entry for approved products.

For deeper insight, consider reviewing ValueRay’s analysis of CMPS.

Headlines to Watch Out For
  • COMP360 Phase III trial results will determine market viability
  • Regulatory approval for psilocybin therapy unlocks revenue streams
  • Competition from other mental health treatments impacts market share
  • Reimbursement policies for psychedelic therapies affect adoption
Piotroski VR‑10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.75 > 0.02 and ΔFCF/TA -18.97 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.75 > 3% & CFO -156.9m > Net Income -287.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 0.77 > 1.5 & < 3
Outstanding Shares: last quarter (93.6m) vs 12m ago 36.76% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -52.41 > 6 (EBITDA TTM -236.1m / Interest Expense TTM 4.51m)
Altman Z'' -15.00
A: -0.27 (Total Current Assets 191.5m - Total Current Liabilities 247.8m) / Total Assets 210.3m
B: -3.91 (Retained Earnings -822.6m / Total Assets 210.3m)
C: -1.11 (EBIT TTM -236.3m / Avg Total Assets 212.0m)
D: -3.18 (Book Value of Equity -836.4m / Total Liabilities 263.2m)
Altman-Z'' Score: -25.33 = D
What is the price of CMPS shares? As of April 13, 2026, the stock is trading at USD 5.53 with a total of 1,306,658 shares traded.
Over the past week, the price has changed by -3.83%, over one month by -16.59%, over three months by -21.00% and over the past year by +83.11%.
Is CMPS a buy, sell or hold? Compass Pathways has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CMPS.
  • StrongBuy: 7
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CMPS price?
Analysts Target Price 21.8 293.3%
Compass Pathways (CMPS) - Fundamental Data Overview as of 09 April 2026
P/B = 16.1106
Revenue TTM = 0.0 USD
EBIT TTM = -236.3m USD
EBITDA TTM = -236.1m USD
Long Term Debt = 14.1m USD (from longTermDebt, last quarter)
Short Term Debt = 19.6m USD (from shortTermDebt, last quarter)
Debt = 35.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -114.6m USD (from netDebt column, last quarter)
Enterprise Value = 599.7m USD (714.2m + Debt 35.0m - CCE 149.6m)
Interest Coverage Ratio = -52.41 (Ebit TTM -236.3m / Interest Expense TTM 4.51m)
EV/FCF = -3.81x (Enterprise Value 599.7m / FCF TTM -157.2m)
FCF Yield = -26.22% (FCF TTM -157.2m / Enterprise Value 599.7m)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 181k) / Revenue TTM)
 Tobins Q-Ratio = 2.85 (Enterprise Value 599.7m / Total Assets 210.3m)
Interest Expense / Debt = 3.24% (Interest Expense 1.14m / Debt 35.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -186.7m (EBIT -236.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.77 (Total Current Assets 191.5m / Total Current Liabilities 247.8m)
 Debt / Equity = -0.66 (negative equity) (Debt 35.0m / totalStockholderEquity, last quarter -52.8m)
 Debt / EBITDA = 0.49 (negative EBITDA) (Net Debt -114.6m / EBITDA -236.1m)
 Debt / FCF = 0.73 (negative FCF - burning cash) (Net Debt -114.6m / FCF TTM -157.2m)
 Total Stockholder Equity = 85.7m (last 4 quarters mean from totalStockholderEquity)
 RoA = -135.8% (out of range, set to none)
 RoE = -335.9% (Net Income TTM -287.9m / Total Stockholder Equity 85.7m)
 RoCE = -236.8% (out of range, set to none) (EBIT -236.3m / Capital Employed (Equity 85.7m + L.T.Debt 14.1m))
 RoIC = -159.9% (out of range, set to none) (NOPAT -186.7m / Invested Capital 116.8m)
 WACC = 10.03% (E(714.2m)/V(749.3m) * Re(10.40%) + D(35.0m)/V(749.3m) * Rd(3.24%) * (1-Tc(0.21)))
Discount Rate = 10.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.93%
 [DCF] Fair Price = unknown (Cash Flow -157.2m)
 EPS Correlation: 7.65 | EPS CAGR: 11.46% | SUE: 1.23 | # QB: 1
Revenue Correlation: -2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.30 | Chg7d=-0.020 | Chg30d=-0.020 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=-1.21 | Chg7d=-0.060 | Chg30d=+0.013 | Revisions Net=+1 | Growth EPS=+31.6% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-1.20 | Chg7d=-0.175 | Chg30d=-0.175 | Revisions Net=-2 | Growth EPS=+1.2% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle